Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.350
-0.340 (-20.12%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2024. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
$75,132
Profits / Employee
-$1,340,485
Market Cap
23.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
LEXX News
- 18 hours ago - Lexaria Announces $2 Million Registered Direct Offering of Common Stock - Accesswire
- 2 days ago - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - Accesswire
- 22 days ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - Accesswire
- 23 days ago - Lexaria's Human GLP-1 Study #5 Begins Dosing - Accesswire
- 5 weeks ago - Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound - TheNewswire
- 5 weeks ago - Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) - Accesswire
- 2 months ago - The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - Accesswire
- 2 months ago - Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - Accesswire